Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle-Associated PDGFRβ

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• BRAF mutant melanoma treatment with kinase inhibitors leads to rapid regression but is often short-lived, with frequent patient relapse.
• The tumor microenvironment, including extracellular vesicles, is increasingly implicated in promoting drug resistance in various cancers.
• The specific role of extracellular vesicles in BRAF inhibitor resistance within melanoma remains largely undefined.

Purpose of the Study:

• To investigate whether extracellular vesicles derived from BRAF inhibitor-resistant melanoma cells can confer drug resistance to sensitive recipient melanoma cells.
• To identify the molecular mechanisms by which extracellular vesicles mediate BRAF inhibitor resistance in melanoma.

Main Methods:

• Utilized BRAF inhibitor-resistant and sensitive melanoma cell lines.
• Isolated and characterized extracellular vesicles (e.g., exosomes) from resistant cells.
• Co-cultured recipient sensitive cells with extracellular vesicles from resistant cells.
• Assessed changes in drug sensitivity, signaling pathway activation (PI3K/AKT, MAPK), and protein transfer (PDGFRβ).

Main Results:

• Extracellular vesicles from BRAF inhibitor-resistant melanoma cells were shown to transfer the resistance driver PDGFRβ (platelet-derived growth factor receptor beta) to recipient melanoma cells.
• Transfer of PDGFRβ via extracellular vesicles led to a dose-dependent activation of the PI3K/AKT signaling pathway in recipient cells.
• This activation resulted in recipient melanoma cells escaping the inhibitory effects of MAPK pathway BRAF inhibition, indicating acquired resistance.
• Demonstrated that extracellular vesicles can alter the drug-sensitive phenotype of metastatic melanoma.

Conclusions:

• Extracellular vesicles act as crucial mediators in the intercellular transfer of drug resistance drivers like PDGFRβ in melanoma.
• The transfer of PDGFRβ via extracellular vesicles promotes BRAF inhibitor resistance by activating the PI3K/AKT pathway, leading to therapeutic escape.
• Targeting extracellular vesicle-mediated communication could represent a novel therapeutic strategy to overcome BRAF inhibitor resistance in metastatic melanoma.